Silver Point

Thomas J. Monaco

Independent Insight Provider

Silver Point is a boutique research firm that focuses on the broader financial services sector, with a particular focus on troubled institutions globally. 

Asia Ex Japan

Equity Bottom-Up

Alibaba Group Holding  / Equity Bottom-Up

*The Hits Just Keep On Coming: Various media outlets have reported that Alibaba Holdings (BABA.US) [BABA] is planning to spend CNY 100 bn (USD 15.4 bn or nearly 2/3 of 2020 earnings) through 2025 in order to support the government's "common prosperity" initiatives – implying another significant earnings hit; and
*FHC Challenges Ahead As Well: BABA’s Ant Group subsidiary is also reorganizing as a financial holding company, and will now be regulated more along the lines of a commercial bank by the China Bank and Insurance Regulatory Commission (CBIRC). As a result, Ant Financial needs to adhere to minimum CAR capital requirements, and follow other bank regulatory guidelines.

*The Hits Just Keep On Coming: Various media outlets have reported that Alibaba Holdings (BABA.US) [BABA] is planning to spend CNY 100 bn (USD 15.4 bn or nearly 2/3 of 2020 earnings) through 2025 in order to support the government's "common prosperity" initiatives – implying another significant earnings hit; and
*FHC Challenges Ahead As Well: BABA’s Ant Group subsidiary is also reorganizing as a financial holding company, and will now be regulated more along the lines of a commercial bank by the China Bank and Insurance Regulatory Commission (CBIRC). As a result, Ant Financial needs to adhere to minimum CAR capital requirements, and follow other bank regulatory guidelines.

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

Last Week in Event SPACE: SingTel, Bharti Airtel, Kerry Logistics, Milton, Jardine Matheson

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Ping An Healthcare and Technology / Equity Bottom-Up

On August 24, 2021, <a href="https://www.smartkarma.com/entities/ping-an-healthcare-and-technology-company-limited" target="_blank" data-smartkarma-citation="entities:27008:1" rel="noopener">Ping An Healthcare and Technology Company Limited (1833 HK) </a>(PAGD) released its 2021 interim results. The revenue was RMB3.82 billion, up 39% YoY. Gross profit was RMB1.025 billion, up 24.8% YoY. Net loss was RMB879.3 million, up 312% YoY. After the financial report was released, PAGD’s share price fell about 13.7% for three consecutive days from August 25, reflecting the attitude of the market. This insight mainly analyzed PAGD in terms of its performance in 2021/1H, the business and the underlying logic, the concerns and the outlook of the Company.

On August 24, 2021, Ping An Healthcare and Technology Company Limited (1833 HK) (PAGD) released its 2021 interim results. The revenue was RMB3.82 billion, up 39% YoY. Gross profit was RMB1.025 billion, up 24.8% YoY. Net loss was RMB879.3 million, up 312% YoY. After the financial report was released, PAGD’s share price fell about 13.7% for three consecutive days from August 25, reflecting the attitude of the market. This insight mainly analyzed PAGD in terms of its performance in 2021/1H, the business and the underlying logic, the concerns and the outlook of the Company.

Ping An Good Doctor (1833.HK) - A Vicious Cycle?

Last Week in Event SPACE: Sembcorp, CK Hutch, Prosus/Naspers, Z Energy, Milton, China Logistics

Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

JD Health International  / Equity Bottom-Up

<a href="https://www.smartkarma.com/entities/jd-health-international-inc" target="_blank" data-smartkarma-citation="entities:29677:1" rel="noopener">JD Health (6618 HK)</a> reported 1H2021 results on Tuesday (24th August) which saw revenues growing 55.4% YoY to RMB13.6bn (vs consensus revenues of RMB9.4bn) driven primarily by the sale of pharmaceutical and healthcare products as a result of expansion in the number of user accounts.The company reported an operating loss for the period compared to an OPM of 4.5% in 1H2020. However, huge share-based payment expense during 1H2021 was the reason for the operating losses during the period and excluding these costs, JD Health made an OPM of 3.4% for 1H2021.JD Health’s shares have lost about 72% since mid-July with the ongoing regulatory overhaul in the Chinese tech sector and news surfacing about the government of China preparing to introduce new regulations to increase supervision of  prescription drugs sold through online platforms.

JD Health (6618 HK) reported 1H2021 results on Tuesday (24th August) which saw revenues growing 55.4% YoY to RMB13.6bn (vs consensus revenues of RMB9.4bn) driven primarily by the sale of pharmaceutical and healthcare products as a result of expansion in the number of user accounts.The company reported an operating loss for the period compared to an OPM of 4.5% in 1H2020. However, huge share-based payment expense during 1H2021 was the reason for the operating losses during the period and excluding these costs, JD Health made an OPM of 3.4% for 1H2021.JD Health’s shares have lost about 72% since mid-July with the ongoing regulatory overhaul in the Chinese tech sector and news surfacing about the government of China preparing to introduce new regulations to increase supervision of  prescription drugs sold through online platforms.

JD Health: Strong Earnings but Regulatory Environment Remains a Concern

China

Alibaba Health Information Technology Limited is an integrated healthcare information and content service provider. The Company uses product identification, authentication, and tracking system data for its healthcare information.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alibaba Health Information Tec (241 HK)

Alibaba Group Holdings - Penance

ALIBABA: BABA is apparently launching a plan to spend CNY 100 bn (nearly 2/3 of 2020 earnings) by 2025 to the "common prosperity" – implying a...

Thomas J. Monaco

Last Week in Event SPACE: SingTel, Bharti Airtel, Kerry Logistics, Milton, Jardine Matheson

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

David Blennerhassett

Ping An Good Doctor (1833.HK) - A Vicious Cycle?

This article mainly analyzed Ping An Good Doctor in terms of its performance in 2021/1H, the business and the underlying logic, the comparison with...

Xinyao (Criss) Wang

Last Week in Event SPACE: Sembcorp, CK Hutch, Prosus/Naspers, Z Energy, Milton, China Logistics

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

David Blennerhassett

JD Health: Strong Earnings but Regulatory Environment Remains a Concern

JD Health’s shares have increased about 3.0% during today's trading despite reporting solid earnings as investors remain concerned over new...

Shifara Samsudeen, ACMA, CGMA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)